CY1112887T1 - Παραγωγα 4-κυκλοαλκυλ-υποκατεστημενης τετραϋδροκινολινης και η χρηση τους ως φαρμακα - Google Patents
Παραγωγα 4-κυκλοαλκυλ-υποκατεστημενης τετραϋδροκινολινης και η χρηση τους ως φαρμακαInfo
- Publication number
- CY1112887T1 CY1112887T1 CY20121100588T CY121100588T CY1112887T1 CY 1112887 T1 CY1112887 T1 CY 1112887T1 CY 20121100588 T CY20121100588 T CY 20121100588T CY 121100588 T CY121100588 T CY 121100588T CY 1112887 T1 CY1112887 T1 CY 1112887T1
- Authority
- CY
- Cyprus
- Prior art keywords
- medicines
- cycloalkyl
- tetrahydroquinoline derivative
- substituted tetrahydroquinoline
- prevention
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010021024 Hypolipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 150000001840 cholesterol esters Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 208000026621 hypolipoproteinemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004061000A DE102004061000A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| DE102004060997A DE102004060997A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| EP05820528A EP1828137B1 (de) | 2004-12-18 | 2005-12-15 | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112887T1 true CY1112887T1 (el) | 2016-04-13 |
Family
ID=35841894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100588T CY1112887T1 (el) | 2004-12-18 | 2012-06-29 | Παραγωγα 4-κυκλοαλκυλ-υποκατεστημενης τετραϋδροκινολινης και η χρηση τους ως φαρμακα |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8124775B2 (enExample) |
| EP (1) | EP1828137B1 (enExample) |
| JP (1) | JP5132317B2 (enExample) |
| KR (1) | KR20070090248A (enExample) |
| AR (1) | AR055011A1 (enExample) |
| AT (1) | ATE555097T1 (enExample) |
| AU (1) | AU2005315770B2 (enExample) |
| BR (1) | BRPI0519602A2 (enExample) |
| CA (1) | CA2591397A1 (enExample) |
| CU (1) | CU23452B7 (enExample) |
| CY (1) | CY1112887T1 (enExample) |
| DK (1) | DK1828137T3 (enExample) |
| DO (1) | DOP2005000259A (enExample) |
| ES (1) | ES2384980T3 (enExample) |
| GT (1) | GT200500377A (enExample) |
| IL (1) | IL184008A (enExample) |
| MA (1) | MA29100B1 (enExample) |
| MX (1) | MX2007007188A (enExample) |
| NO (1) | NO20073146L (enExample) |
| PE (1) | PE20060767A1 (enExample) |
| PL (1) | PL1828137T3 (enExample) |
| PT (1) | PT1828137E (enExample) |
| RU (1) | RU2393151C2 (enExample) |
| SI (1) | SI1828137T1 (enExample) |
| TW (1) | TW200635900A (enExample) |
| UY (1) | UY29276A1 (enExample) |
| WO (1) | WO2006063828A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1828136A1 (de) * | 2004-12-18 | 2007-09-05 | Bayer HealthCare AG | (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren |
| DE102006012548A1 (de) * | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| AU2009221179A1 (en) * | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| AU2011217206A1 (en) | 2010-02-19 | 2012-08-02 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| MX2013000359A (es) * | 2010-07-09 | 2013-02-11 | Ube Industries | Compuesto de piridina sustituida. |
| EP2675811A1 (en) | 2011-02-17 | 2013-12-25 | Boehringer Ingelheim International GmbH | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| EP2760868B1 (en) | 2011-08-17 | 2018-04-25 | Boehringer Ingelheim International GmbH | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
| CA2860601C (en) | 2012-01-06 | 2016-07-05 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| WO2025185022A1 (zh) * | 2024-03-05 | 2025-09-12 | 维康平生(北京)生物科技有限公司 | 一种脂肪体的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128681A1 (de) * | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DE19610932A1 (de) * | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19627430A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19704244A1 (de) * | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| MA24643A1 (fr) * | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741051A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| DE19935966A1 (de) | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| DE10148436A1 (de) * | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| DE10250687A1 (de) * | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
| EP1828136A1 (de) * | 2004-12-18 | 2007-09-05 | Bayer HealthCare AG | (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren |
-
2005
- 2005-12-15 MX MX2007007188A patent/MX2007007188A/es active IP Right Grant
- 2005-12-15 RU RU2007127127/04A patent/RU2393151C2/ru not_active IP Right Cessation
- 2005-12-15 AU AU2005315770A patent/AU2005315770B2/en not_active Ceased
- 2005-12-15 PT PT05820528T patent/PT1828137E/pt unknown
- 2005-12-15 DK DK05820528.7T patent/DK1828137T3/da active
- 2005-12-15 CA CA002591397A patent/CA2591397A1/en not_active Abandoned
- 2005-12-15 US US11/793,482 patent/US8124775B2/en not_active Expired - Fee Related
- 2005-12-15 EP EP05820528A patent/EP1828137B1/de not_active Expired - Lifetime
- 2005-12-15 AT AT05820528T patent/ATE555097T1/de active
- 2005-12-15 JP JP2007545948A patent/JP5132317B2/ja not_active Expired - Fee Related
- 2005-12-15 PL PL05820528T patent/PL1828137T3/pl unknown
- 2005-12-15 BR BRPI0519602-7A patent/BRPI0519602A2/pt not_active IP Right Cessation
- 2005-12-15 SI SI200531547T patent/SI1828137T1/sl unknown
- 2005-12-15 WO PCT/EP2005/013490 patent/WO2006063828A1/de not_active Ceased
- 2005-12-15 KR KR1020077016219A patent/KR20070090248A/ko not_active Ceased
- 2005-12-15 ES ES05820528T patent/ES2384980T3/es not_active Expired - Lifetime
- 2005-12-16 AR ARP050105313A patent/AR055011A1/es not_active Application Discontinuation
- 2005-12-16 PE PE2005001475A patent/PE20060767A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144588A patent/TW200635900A/zh unknown
- 2005-12-16 DO DO2005P000259A patent/DOP2005000259A/es unknown
- 2005-12-19 GT GT200500377A patent/GT200500377A/es unknown
- 2005-12-20 UY UY29276A patent/UY29276A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 CU CU20070140A patent/CU23452B7/es not_active IP Right Cessation
- 2007-06-18 IL IL184008A patent/IL184008A/en not_active IP Right Cessation
- 2007-06-18 MA MA30003A patent/MA29100B1/fr unknown
- 2007-06-19 NO NO20073146A patent/NO20073146L/no not_active Application Discontinuation
-
2012
- 2012-02-16 US US13/398,290 patent/US20120142728A1/en not_active Abandoned
- 2012-06-29 CY CY20121100588T patent/CY1112887T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY29276A1 (es) | 2006-07-31 |
| CU23452B7 (es) | 2009-12-01 |
| US20080255068A1 (en) | 2008-10-16 |
| GT200500377A (es) | 2006-11-09 |
| IL184008A0 (en) | 2007-10-31 |
| ES2384980T3 (es) | 2012-07-16 |
| PL1828137T3 (pl) | 2012-09-28 |
| KR20070090248A (ko) | 2007-09-05 |
| TW200635900A (en) | 2006-10-16 |
| AR055011A1 (es) | 2007-08-01 |
| RU2393151C2 (ru) | 2010-06-27 |
| JP2008524145A (ja) | 2008-07-10 |
| AU2005315770A1 (en) | 2006-06-22 |
| PE20060767A1 (es) | 2006-09-10 |
| EP1828137B1 (de) | 2012-04-25 |
| WO2006063828A1 (de) | 2006-06-22 |
| DK1828137T3 (da) | 2012-07-23 |
| US8124775B2 (en) | 2012-02-28 |
| ATE555097T1 (de) | 2012-05-15 |
| NO20073146L (no) | 2007-09-18 |
| DOP2005000259A (es) | 2006-11-15 |
| BRPI0519602A2 (pt) | 2009-02-25 |
| RU2007127127A (ru) | 2009-01-27 |
| MA29100B1 (fr) | 2007-12-03 |
| IL184008A (en) | 2012-03-29 |
| SI1828137T1 (sl) | 2012-08-31 |
| US20120142728A1 (en) | 2012-06-07 |
| MX2007007188A (es) | 2007-08-14 |
| EP1828137A1 (de) | 2007-09-05 |
| PT1828137E (pt) | 2012-07-04 |
| CA2591397A1 (en) | 2006-06-22 |
| AU2005315770B2 (en) | 2011-12-08 |
| JP5132317B2 (ja) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118898T1 (el) | Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης | |
| CY1122629T1 (el) | Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
| EA200702674A1 (ru) | Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции | |
| EP1929073A4 (en) | PROTEIN MEDICAMENT AND ITS USE | |
| CY1121070T1 (el) | Φαρμακευτικες συνθεσεις για την αγωγη cftr μεσολαβουμενων παθησεων | |
| CY1112813T1 (el) | 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| NO20073146L (no) | 4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter | |
| ATE390925T1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
| BRPI0519566A2 (pt) | derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| CY1112115T1 (el) | Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου | |
| BRPI0514133A (pt) | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i | |
| CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
| LT2878297T (lt) | Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai | |
| SE0303570L (sv) | Fukt-känslig medicinsk produkt | |
| CY1108937T1 (el) | Χρηση της κινασης πρωτεϊνης ν-β | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| EA202191244A1 (ru) | Новые цитостатические конъюгаты с лигандами интегрина | |
| CL2007003209A1 (es) | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion | |
| EP2233504A4 (en) | A ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALT, ITS PREPARATION AND ITS APPLICATIONS | |
| CY1114857T1 (el) | Τροποποιημενα ενζυμα λεκιθινο-χοληστερολικης ακυλοτρανσφερασης | |
| DK1542729T3 (da) | Stabilt immunogent produkt omfattende antigene heterokomplekser | |
| CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης |